^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FCGR3A V158F

    i
    Other names: FCGR3A, Fc Fragment Of IgG Receptor IIIa, Low Affinity Immunoglobulin Gamma Fc Region Receptor III-A, Fc Fragment Of IgG Low Affinity IIIa Receptor (CD16a), IgG Fc Receptor III-2, Fc-Gamma RIII-Alpha, CD16a Antigen, FCGR3, CD16A, IGFR3, FCG3, Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment 3, Fc Fragment Of IgG Low Affinity IIIa Receptor For (CD16), Fc Fragment Of IgG Low Affinity III Receptor For (CD16), Immunoglobulin G Fc Receptor III, Fc-Gamma Receptor III-2 (CD 16), Neutrophil-
    Entrez ID:
    2214
    Related biomarkers:
    Mutation
    Associations

    News

    Trials
    2ms
    FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients. (PubMed, Sci Rep)
    V/V is associated with better treatment response and overall survival (OS) compared to F/V and F/F alleles. Assessment of FCGR3A-V158F gene polymorphism might be useful in making a treatment decision in HER2-positive breast cancer patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    HER-2 positive • FCGR3A V158F
    |
    Herceptin (trastuzumab)
    over4years
    Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. (PubMed, J Immunother Cancer)
    These results suggest that NK cells induce an ADCC response in combination with anti-PD-L1 mAbs, which helps promote ADCC antitumor activity against PD-L1-positive tumors. This study provides support for NK cell immunotherapy against high PD-L1-expressing tumors in combination with ADCC through anti-PD-L1 mAbs.
    Preclinical • Journal • PD(L)-1 Biomarker
    |
    PD-1 (Programmed cell death 1) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    PD-L1 expression • PD-L1 overexpression • FCGR3A V158F
    |
    Tecentriq (atezolizumab) • IMC-001